(Lung Cancer) anti-PD-L1 antibody as First-Line Treatment?
(Lung Cancer) anti-PD-L1 antibody as First-Line Treatment?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
(Lung Cancer) anti-PD-L1 antibody as First-Line Treatment?
- December 18, 2019
- 2 min read
Updated: January 27, 2020
On September 27, 2019, Roche announced that the anti-PD-L1 antibody drug atezolizumab showed favorable efficacy and safety results as first-line treatment in non-squamous/squamous non-small cell lung cancer patients in the IMpower110 Phase III clinical trial.
The IMpower110 Phase III clinical trial enrolled squamous/non-squamous non-small cell lung cancer patients without ALK fusion gene or EGFR mutation (N=572), randomized 1:1 into a anti-PD-L1 antibody monotherapy group and a chemotherapy group (cisplatin or carboplatin + pemetrexed disodium or gemcitabine). The primary endpoint was overall survival stratified by PD-L1 expression, with secondary endpoints including progression-free survival, objective response rate, and safety.
The trial results showed that in patients with high PD-L1 expression, the median overall survival for the primary endpoint was: anti-PD-L1 antibody monotherapy group 20.2 months vs. chemotherapy group 13.1 months. The anti-PD-L1 antibody monotherapy group showed a 40.5% reduction in overall survival risk, with a hazard ratio of 0.595, demonstrating significant improvement.
In patients with intermediate PD-L1 expression, the median survival was: anti-PD-L1 antibody monotherapy group 18.2 months vs. chemotherapy group 14.9 months. The anti-PD-L1 antibody monotherapy group showed a 28.3% reduction in overall survival risk, with a hazard ratio of 0.717, showing no significant improvement. Analysis of overall survival in patients with low PD-L1 expression is still ongoing.
Regarding safety, grade 3 adverse event rates were: anti-PD-L1 antibody monotherapy group 60.5% vs. chemotherapy group 85.2%. Grade 4 adverse event rates were: anti-PD-L1 antibody monotherapy group 12.9% vs. chemotherapy group 44.1%.
Based on the IMpower110 trial results, Sandra Horning concluded that the anti-PD-L1 antibody drug anti-PD-L1 antibody as first-line treatment in non-squamous/squamous non-small cell lung cancer patients demonstrated improved overall survival in patients with high PD-L1 expression.
[Disclaimer] The clinical trial data and pharmaceutical information from overseas trials translated by "Medical Supporter" are not intended to encourage participation in clinical trials or the use of any new drugs. The translated materials are for reference only and do not constitute medication guidelines. Please consult with your healthcare professionals, and refer to the original text below for accurate content.
Source: Roche Press Release
#LungCancer #anti-PD-L1 antibody
-
Investigational drugs
(Lung Cancer) Topotecan and Topotecan + Berzosertib Phase II clinical trial results. (Lung Cancer) Is anti-HER2 antibody-drug conjugate effective for HER2-mutant non-small cell lung cancer? (Lung Cancer) Is anti-B7-H3 antibody drug DS-7300 effective?
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free (initial direction only; further services are quoted separately); an advisor will help you clarify the next steps.